Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 8/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9206085 | 1.00 | EPHX1 (0.39) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL9204096 | 1.00 | EPHX1 (0.39) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL27743520 | 1.00 | EPHX1 (0.39) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL9205901 | 1.00 | EPHX1 (0.39) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| Hydrochloric Acid SCHEMBL28769674 | 0.98 | EPHX1 (0.37) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL11416088 | 0.91 | EPHX1 (0.44) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL21236821 | 0.91 | EPHX1 (0.44) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL8755205 | 0.91 | EPHX1 (0.44) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL22623546 | 0.91 | EPHX1 (0.44) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL22436200 | 0.91 | EPHX1 (0.39) | EPHX1TSHRTHRBALDH1A1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174554-A1 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF | Boehringer Ingelheim Vetmedica GmbH (DE) | 2017-06-07 | — | — | EP | claimed |
| US-20160030349-A1 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2016-02-04 | — | — | US | claimed |
| WO-2016016401-A1 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2016-02-04 | — | — | WO | claimed |
| EP-1572729-B1 | MUTANT FRPB PROTEIN AND REFOLDING METHOD | GLAXOSMITHKLINE BIOLOG SA (BE) | 2010-09-22 | — | — | EP | claimed |
| EP-0805678-B1 | SURFACE-MODIFIED NANOPARTICLES AND METHOD OF MAKING AND USING SAME | UNIV MICHIGAN (US) | 2003-10-29 | — | — | EP | claimed |
| EP-0760519-B1 | Process for manufacturing nuclear fuel pellets based on (U,PU)02 with addition of an organic sulphur zwitterion compound | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 1999-07-07 | — | — | EP | claimed |
| US-5841200-A | Process for the production of nuclear fuel pellets based on mixed (U, Pu)O2 oxide with the addition of an organic, sulphur product | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1998-11-24 | — | — | US | claimed |
| EP-0805678-A1 | SURFACE-MODIFIED NANOPARTICLES AND METHOD OF MAKING AND USING SAME | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996020698-A2 | SURFACE-MODIFIED NANOPARTICLES AND METHOD OF MAKING AND USING SAME | THE BOARD OF REGENTS ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF MICHIGAN (US) | 1996-07-11 | — | — | WO | claimed |
| EP-4701672-A1 | INJECTABLE SHEAR-THINNING COMPOSITIONS AND USES THEREOF | Boston Scientific Scimed Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024226987-A1 | INJECTABLE SHEAR-THINNING COMPOSITIONS AND USES THEREOF | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240358892-A1 | INJECTABLE SHEAR-THINNING COMPOSITIONS AND USES THEREOF | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-3174554-A1 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF | Boehringer Ingelheim Vetmedica GmbH (DE) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016401-A1 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
| EP-0805678-A1 | SURFACE-MODIFIED NANOPARTICLES AND METHOD OF MAKING AND USING SAME | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0760519-A1 | Process for manufacturing nuclear fuel pellets based on (U,PU)02 with addition of an organic sulphur compound | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996020698-A2 | SURFACE-MODIFIED NANOPARTICLES AND METHOD OF MAKING AND USING SAME | THE BOARD OF REGENTS ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF MICHIGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030349-A1 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF | MYD88, TLR3, CD63 | EPHX1 1012/4885TSHR 4703/4885THRB 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.